They are due in three days' time. And, this is why you ought to send in your commentary to ECC, as I've set forth in four prior posts (see below) -- courtesy of Arnold & Porter's EU antitrust lawyers (at the top of page 43, of this PDF file):
. . . .15. In what circumstances will a product and geographical overlap between two merging EU parties be considered problematic?
Horizontal mergers between firms are potentially problematic when the aggregate market share of the merging firms exceeds 40 percent, provided the increment caused by the merger is not negligible. See, e.g., Schering Plough/Organon (2007), Sanofi-Synthelabo/Aventis (2004) and Pfizer/Warner Lambert (2000).
The Commission may also intervene when the overlap between the merging parties’ products has not yet materialised. In other words, potential competition from pipeline products is also taken into account if there is a reasonable chance that these products will make it to the market. . . .
Just click this, or put "Merial" in the search box at the top of the blog.
No comments:
Post a Comment